Two former Trump administration officials have taken to the Wall Street Journal to defend the practices of pharmacy benefit managers, the middlemen who negotiate drug prices with the manufacturers on behalf of the insurers. The authors are perplexed as to why fellow Republicans would be concerned about these middlemen using their leverage to extract “rebates”...
Prescription drugs are the difference between life and death for millions of Americans each day, yet their costs are far too often unaffordable. Heavily influencing these prices are Pharmacy Benefit Managers (PBMs). These are the third-party middlemen who negotiate prescription drug rates with pharmaceutical manufacturers on behalf of insurance companies. Earlier this month, the Federal...
Section 1332 waivers offer states an opportunity to avoid the centralized policies of the ACA and craft innovative health insurance reforms specific to their distinctive populations and markets without increasing federal spending. Key points A number of the ACA’s centralized regulations have stifled innovation, de-stabilized the individual health insurance market, and contributed to an increase...